Cordant Inc’s Sage Therapeutics SAGE Stock Holding History

Cordant Inc’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	–	–	1027
2022 Q1	$0	Buy	+4	New	+$150	﹤0.01%	1359

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cordant Inc's SAGE Position: Q2 2022 in Review

Cordant Inc sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 4 shares.

Cordant Inc first reported a position in SAGE in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

Cordant Inc reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 4 Sage Therapeutics shares in Q2 2022.
Cordant Inc first reported a position in Sage Therapeutics in Q1 2022 and held it in 1 quarter.
Cordant Inc's Sage Therapeutics position peaked at $0 in Q1 2022.
209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.